Literature DB >> 26110426

Transfemoral aortic valve implantation in pure native aortic valve insufficiency using the repositionable and retrievable lotus valve.

Jochen Wöhrle1, Christoph Rodewald1, Wolfgang Rottbauer1.   

Abstract

Transfemoral aortic valve implantation (TAVI) for the treatment of pure native aortic insufficiency is not routine clinical practice. Absent cusp calcification, missing landmarks in combination with no perfect valve control during release with first-generation TAVI devices resulted in a high rate for need of a second valve or relevant residual aortic insufficiency. We report the first case with a native pure aortic valve insufficiency at high surgical risk successfully treated by implantation of the repositionable and completely retrievable Lotus valve, resulting in a well-controlled and safe procedure with no residual aortic insufficiency.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  AVD-aortic valve disease; AVDP-aortic valve disease; TVI-transcatheter valve implantation; percutaneous intervention

Mesh:

Year:  2015        PMID: 26110426     DOI: 10.1002/ccd.26062

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  8 in total

1.  Transcatheter aortic valve implantation with the repositionable and fully retrievable Lotus Valve SystemTM.

Authors:  Rodrigo Bagur; Tawfiq Choudhury; Mamas A Mamas
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

2.  Editorial comment on the RESPOND study.

Authors:  Daniel Wendt; Matthias Thielmann; Sharaf Eldin Shehada; Konstantinos Tsagakis; Heinz Jakob; Mohamed El Gabry
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 3.  The Lotus Valve System: an In-depth Review of the Technology.

Authors:  Matthew E Seigerman; Ashwin Nathan; Saif Anwaruddin
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

4.  Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve.

Authors:  Birgid Gonska; Julia Seeger; Mirjam Keßler; Alexander von Keil; Wolfgang Rottbauer; Jochen Wöhrle
Journal:  Clin Res Cardiol       Date:  2017-03-10       Impact factor: 5.460

Review 5.  TAVI for Pure Native Aortic Regurgitation: Are We There Yet?

Authors:  Eduardo A Arias; Amit Bhan; Zhan Y Lim; Michael Mullen
Journal:  Interv Cardiol       Date:  2019-02

6.  Transfemoral Aortic Valve Implantation with the New Edwards Sapien 3 Valve for Treatment of Severe Aortic Stenosis-Impact of Valve Size in a Single Center Experience.

Authors:  Jochen Wöhrle; Birgid Gonska; Christoph Rodewald; Julia Seeger; Dominik Scharnbeck; Wolfgang Rottbauer
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

7.  Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up.

Authors:  Fei Li; Xu Wang; Yuetang Wang; Fei Xu; Xin Wang; Xuan Li; Wei Wang
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-04-03       Impact factor: 1.520

8.  Influence of permanent pacemaker implantation after transcatheter aortic valve implantation with new-generation devices.

Authors:  B Gonska; M Keßler; J Wöhrle; W Rottbauer; J Seeger
Journal:  Neth Heart J       Date:  2018-12       Impact factor: 2.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.